Zydus Cadila receives tentative approval from USFDA for lung cancer drugs
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Subscribe To Our Newsletter & Stay Updated